Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 172

Similar articles for PubMed (Select 21118051)

1.

Performance of nuclear matrix protein 22 urine marker and voided urine cytology in the detection of urinary bladder tumors.

Smrkolj T, Mihelič M, Sedlar A, Sterle I, Osredkar J, Sedmak B.

Clin Chem Lab Med. 2011 Feb;49(2):311-6. doi: 10.1515/CCLM.2011.038. Epub 2010 Dec 1.

PMID:
21118051
2.

Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.

Kumar A, Kumar R, Gupta NP.

Jpn J Clin Oncol. 2006 Mar;36(3):172-5. Epub 2006 Mar 6.

3.

Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.

Shariat SF, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI.

Eur Urol. 2004 Mar;45(3):304-13; author reply 313.

PMID:
15036675
4.

Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.

Moonen PM, Kiemeney LA, Witjes JA.

Eur Urol. 2005 Dec;48(6):951-6; discussion 956. Epub 2005 Sep 26.

PMID:
16257108
5.
6.

Role of NMP22 Bladder Check Test in early detection of bladder cancer with recurrence.

Kundal VK, Pandith AA, Hamid A, Shah A, Kundal R, Wani SM.

Asian Pac J Cancer Prev. 2010;11(5):1279-82.

8.

[The use of NMP22 Bladder-Chek for the diagnosis and follow-up bladder cancer].

Gonzalo Rodríguez V, Sanz Justo L, de Miguel Santamaría I, Martínez de Iturrate J, Fernández del Busto E.

Arch Esp Urol. 2008 Apr;61(3):377-84. Spanish.

PMID:
18581675
9.

Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?

Mahnert B, Tauber S, Kriegmair M, Nagel D, Holdenrieder S, Hofmann K, Reiter W, Schmeller N, Stieber P.

Clin Chem Lab Med. 2003 Jan;41(1):104-10.

PMID:
12636058
10.

Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.

Kehinde EO, Al-Mulla F, Kapila K, Anim JT.

Scand J Urol Nephrol. 2011 Mar;45(2):113-21. doi: 10.3109/00365599.2010.533694. Epub 2010 Nov 22.

PMID:
21091091
11.

NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.

Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A.

Anticancer Res. 1999 Jul-Aug;19(4A):2621-3.

PMID:
10470205
12.

Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.

Tritschler S, Scharf S, Karl A, Tilki D, Knuechel R, Hartmann A, Stief CG, Zaak D.

Eur Urol. 2007 Feb;51(2):403-7; discussion 407-8. Epub 2006 Aug 15.

PMID:
16939699
14.

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.

Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, Shen Y.

JAMA. 2006 Jan 18;295(3):299-305.

PMID:
16418465
15.

[Clinical evaluation of urinary NMP22 (nuclear matrix protein 22) bladder chek in the detection of patients with bladder cancer].

Kitsukawa S, Yamamoto Y, Hosoda S, Otsuru N, Matsumoto T, Matsumoto T, Aizawa T, Noda K, Ito T.

Hinyokika Kiyo. 2006 Mar;52(3):167-72. Japanese.

PMID:
16617867
17.

Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.

Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS.

J Urol. 1998 Feb;159(2):394-8. Erratum in: J Urol 1998 May;159(5):1650.

PMID:
9649246
18.

Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer?

Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M.

J Urol. 1998 Jun;159(6):1876-80.

PMID:
9598479
19.

[Cytokeratins (UBC and CYFRA 21-1) and nuclear matrix proteins (NMP22) as urine tumor markers in the diagnosis of bladder cancer].

Sánchez-Carbayo M, Urrutia M, Hernández-Cerceño ML, González de Buitrago JM, Navajo JA.

Med Clin (Barc). 2000 Mar 18;114(10):361-6. Spanish.

PMID:
10786344
20.

Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.

Kapila K, Kehinde EO, Anim JT, Mojiminiyi OA, Vinsu A, George SS, Al-Maghrebi M, Al-Mulla F.

Cytopathology. 2008 Dec;19(6):369-74. doi: 10.1111/j.1365-2303.2008.00586.x. Epub 2008 Jul 9.

PMID:
18631356
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk